LeonaBio, Inc. Insider Trading

LONA

Last 12 months

Insiders sold 99K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Medical Officer Martin Javier San sold 11K on Jan 2, 14% of their stake, outside a plan. The last open-market buy by an executive or director was in Jun 2024.

Net open-market

−99K

0 buys · 10 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Jun 2024

Jun 24, 2024

Get an email when LONA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 26	David J. Portman Large holder	Bought	3,149,470	$3,149.47	$9.92B	New	Form 4
Mar 4	Robert Renninger Chief Financial Officer	SoldNo plan	906	$5.37	5K	5.4%	Form 4
Mar 4	Mark Worthington GENERAL COUNSEL and CCO	SoldNo plan	1,328	$5.37	7K	6.7%	Form 4
Mar 4	Kevin Church Chief Scientific Officer	SoldNo plan	1,359	$5.37	7K	5.1%	Form 4
Mar 4	Martin Javier San Chief Medical Officer	SoldNo plan	1,720	$5.37	9K	9.8%	Form 4
Mar 4	Mark James Litton PRESIDENT and CEO	SoldNo plan	5,156	$5.37	28K	7.9%	Form 4
Jan 2	Robert Renninger Chief Financial Officer	SoldNo plan	297	$6.88	2K	2.3%	Form 4
Jan 2	Mark Worthington General Counsel and CCO	SoldNo plan	876	$6.88	6K	5.9%	Form 4
Jan 2	Kevin Church Chief Scientific Officer	SoldNo plan	876	$6.88	6K	4.1%	Form 4
Jan 2	Martin Javier San Chief Medical Officer	SoldNo plan	1,644	$6.88	11K	14%	Form 4
Jan 2	Mark James Litton President and CEO	SoldNo plan	2,586	$6.88	18K	5.7%	Form 4
Jul 1, 2025	Kevin Church Chief Scientific Officer	SoldNo plan	8,526	$0.29	2K	4.8%	Form 4
Jul 1, 2025	Mark James Litton President and CEO	SoldNo plan	25,123	$0.29	7K	6.8%	Form 4
Jul 1, 2025	Martin Javier San Chief Medical Officer	SoldNo plan	10,842	$0.29	3K	13%	Form 4
Jul 1, 2025	Mark Worthington General Counsel and CCO	SoldNo plan	8,526	$0.29	2K	7.1%	Form 4
Jul 1, 2025	Robert Renninger SVP, Finance and Accounting	SoldNo plan	2,897	$0.29	$840	2.6%	Form 4
Jan 2, 2025	Martin Javier San Chief Medical Officer	SoldNo plan	10,826	$0.56	6K	23%	Form 4
Jan 2, 2025	Mark James Litton President and CEO	SoldNo plan	25,107	$0.56	14K	8.7%	Form 4
Jan 2, 2025	Kevin Church Chief Scientific Officer	SoldNo plan	8,510	$0.56	5K	6.1%	Form 4
Jan 2, 2025	Robert Renninger VP of Finance	SoldNo plan	2,881	$0.56	2K	3.1%	Form 4
Jan 2, 2025	Mark Worthington General Counsel and CCO	SoldNo plan	8,510	$0.56	5K	9.2%	Form 4

Oct 26
David J. Portman
Large holder · bought 3,149,470 at $3,149.47
$9.92B
New position
Mar 4No plan
Robert Renninger
Chief Financial Officer · sold 906 at $5.37
5K
5.4% of stake
Mar 4No plan
Mark Worthington
GENERAL COUNSEL and CCO · sold 1,328 at $5.37
7K
6.7% of stake
Mar 4No plan
Kevin Church
Chief Scientific Officer · sold 1,359 at $5.37
7K
5.1% of stake
Mar 4No plan
Martin Javier San
Chief Medical Officer · sold 1,720 at $5.37
9K
9.8% of stake
Mar 4No plan
Mark James Litton
PRESIDENT and CEO · sold 5,156 at $5.37
28K
7.9% of stake
Jan 2No plan
Robert Renninger
Chief Financial Officer · sold 297 at $6.88
2K
2.3% of stake
Jan 2No plan
Mark Worthington
General Counsel and CCO · sold 876 at $6.88
6K
5.9% of stake
Jan 2No plan
Kevin Church
Chief Scientific Officer · sold 876 at $6.88
6K
4.1% of stake
Jan 2No plan
Martin Javier San
Chief Medical Officer · sold 1,644 at $6.88
11K
14% of stake
Jan 2No plan
Mark James Litton
President and CEO · sold 2,586 at $6.88
18K
5.7% of stake
Jul 1, 2025No plan
Kevin Church
Chief Scientific Officer · sold 8,526 at $0.29
2K
4.8% of stake
Jul 1, 2025No plan
Mark James Litton
President and CEO · sold 25,123 at $0.29
7K
6.8% of stake
Jul 1, 2025No plan
Martin Javier San
Chief Medical Officer · sold 10,842 at $0.29
3K
13% of stake
Jul 1, 2025No plan
Mark Worthington
General Counsel and CCO · sold 8,526 at $0.29
2K
7.1% of stake
Jul 1, 2025No plan
Robert Renninger
SVP, Finance and Accounting · sold 2,897 at $0.29
$840
2.6% of stake
Jan 2, 2025No plan
Martin Javier San
Chief Medical Officer · sold 10,826 at $0.56
6K
23% of stake
Jan 2, 2025No plan
Mark James Litton
President and CEO · sold 25,107 at $0.56
14K
8.7% of stake
Jan 2, 2025No plan
Kevin Church
Chief Scientific Officer · sold 8,510 at $0.56
5K
6.1% of stake
Jan 2, 2025No plan
Robert Renninger
VP of Finance · sold 2,881 at $0.56
2K
3.1% of stake
Jan 2, 2025No plan
Mark Worthington
General Counsel and CCO · sold 8,510 at $0.56
5K
9.2% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LONA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with LONA

CompareIntrinsic value

CVMCel-Sci Corporation

$1.38-2.13%0

ARMPArmata Pharmaceuticals Inc.

$3.14+1.62%30

PLURPluri Inc.

$1.23-3.15%30

BCABBioAtla, Inc.

$2.00+0.00%0

STROSutro Biopharma, Inc.

$9.94+4.52%10

RVMDRevolution Medicines Inc.

$199.21+2.56%10

APTOFAptose Biosciences Inc.

No recent price10

ELOXEloxx Pharmaceuticals, Inc.

$12.74-1.39%20

Held by ETFs

LONA is in 1 US ETF. The largest of them, with LONA's weight in each:

Simplify Propel Opportunities ETFSURI1.78%of the fund

Spot a number that looks wrong? Check it in LONA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LONA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.